Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mesenchymal tumor cells drive adaptive resistance of Trp53-/- breast tumor cells to inactivated mutant Kras.

Molecular oncology - 1 Sept 2022

van Weele Linda J, Djomehri Sabra I, Cai Shang, Antony Jane, Sikandar Shaheen S, Qian Dalong, Ho William H D, West Robert B, Scheeren Ferenc A, Clarke Michael F

Abstract excerpt

As precision medicine increases the response rate of treatment, tumors frequently bypass inhibition, and reoccur. In order for treatment to be effective long term, the mechanisms enabling treatment adaptation need to be understood. Here, we report a mouse model that, in the absence of p53 and the presence of oncogenic KrasG12D , develops breast tumors. Upon inactivation of KrasG12D , tumors initially regress and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Epithelial-Mesenchymal Transition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to MAP Kinase Signaling System

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 35398967
DOI: 10.1002/1878-0261.13220
PMCID: PMC9441006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mesenchymal tumor cells drive adaptive resistance of Trp53-/- breast tumor cells to inactivated mutant Kras.PMID 35398967Read ↗

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culpritSemantic proximity Read ↗

Behind the Wheel of Epithelial Plasticity in KRAS-Driven CancersSemantic proximity Read ↗

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.Semantic proximity Read ↗

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read ↗

Adaptive selection of p53 mutation metaplastic phenotypes in estrogen-independent progression of ER+ tumors: A mechanism for acquired resistance to hormonal therapySemantic proximity Read ↗

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in <i>KRAS</i> -Mutant CancersSemantic proximity Read ↗

Unraveling the dangerous duet between cancer cell plasticity and drug resistanceSemantic proximity Read ↗

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCSemantic proximity Read ↗

Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticitySemantic proximity Read ↗

Direct reprogramming by oncogenic Ras and Myc.Semantic proximity Read ↗

BRCA1 and BRCA2 germline mutations driven signaling pathway alterations are sufficient to initiate breast tumorigenesis by the PIK3CA <sup>H1047R</sup> oncogeneSemantic proximity Read ↗

Oncogenic transformation proceeds through a transient state of cellular plasticity constrained by lineage-specific barriersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.